Please assess the completion status of the following clinical trial:

Trial Title: Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed, written, and dated informed consent prior to any study-specific procedures~2. Healthy subjects must be able to understand and be willing to comply with study procedures, restrictions, and requirements.~3. Male and non-fertile female healthy subjects, aged 18 to 55 years~4. Body weight ≥50 to ≤100 kg and body mass index (BMI) ≥19 to ≤30 kg/m2~5. Clinically normal findings on physical examination in relation to age, as judged by the Investigator~Exclusion Criteria:~1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study~2. History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs~3. History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder according to the criteria in the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV), as assessed by the Mini-International Neuropsychiatric Interview (MINI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- AZD3293 oral solution (Type: EXPERIMENTAL): single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
- AZD3293 tablet formulation A (Type: EXPERIMENTAL): single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)
- AZD3293 tablet formulation B (Type: EXPERIMENTAL): single doses in random order in 3 study periods for each subject (Day 1 or Day 8 or Day 15)

Based on this trial design, predict the completion outcome and termination type (if applicable).